Sage Journals: Discover world-class research

Open access

Review article

First published 2020

Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer

Pernelle Lavaud, Clément Dumont, Constance Thibault [...]

Therapeutic Advances in Medical Oncology

Open access

Review article

First published 2019

The Current Landscape of Treatment in Non-Metastatic Castration-Resistant Prostate Cancer

Joelle El-Amm, Jeanny B Aragon-Ching

Clinical Medicine Insights: Oncology

Retricted access

Case report

First published 2023-10

Apalutamide-induced lichenoid reaction in a patient with non-metastatic castrate-resistant prostate cancer

Malvina Cremante, Silvia Puglisi, Annalice Gandini [...]

Journal of Oncology Pharmacy Practice

Open access

Research article

First published 2022

GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol)

Ciara Conduit, Blossom Mak, Wenjia Qu [...]

Therapeutic Advances in Medical Oncology

Retricted access

Review article

First published 2023-11

Updates in the Treatment of Non-Metastatic Castrate-Resistant Prostate Cancer: The Benefit of Second-Generation Androgen Receptor Antagonists

Matthew J. Hadfield, Vikram Lyall, Lisa M. Holle [...]

Annals of Pharmacotherapy

Open access

Research article

First published 2026

Cost-effectiveness of novel antiandrogens for the treatment of nmCRPC patients in the Chinese healthcare system

Wenjuan Yang, Bei Zheng, Mengyue Zhou [...]

Therapeutic Advances in Urology

Open access

Review article

First published 2023

Androgen receptor pathway inhibitors,prostate cancer,and older adults: a global Young International Society of Geriatric Oncology drug review

Nabiel Mir, Olivia Burke, Samuel Yates [...]

Therapeutic Advances in Medical Oncology

Open access

Correction

First published 2022

Corrigendum to “GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol)”

Therapeutic Advances in Medical Oncology

Retricted access

Review article

First published 2022-04

Myeloid Toxicity of Radionuclide Cancer Therapy

Murali Kesavan, J. Harvey Turner

Cancer Biotherapy and Radiopharmaceuticals

Open access

Research article

First published 2018-4

Dual PI3 K/mTOR inhibition reduces prostate cancer bone engraftment altering tumor-induced bone remodeling

Andrea Mancini, Alessandro Colapietro, Simona Pompili [...]

Tumor Biology

Search results